The DOI matches its Crossref record; 255 of the 256 references it cites were found in a registry or an index.
mRNA-based therapeutics--developing a new class of drugs
Open accessAbstract
In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to deliver genetic information. Such synthetic mRNA can be engineered to transiently express proteins by structurally resembling natural mRNA. Advances in addressing the inherent challenges of this drug class, particularly related to controlling the translational efficacy and immunogenicity of the IVTmRNA, provide the basis for a broad range of potential applications. mRNA-based cancer immunotherapies and infectious disease vaccines have entered clinical development. Meanwhile, emerging novel approaches include in vivo delivery of IVT mRNA to replace or supplement proteins, IVT mRNA-based generation of pluripotent stem cells and genome engineering using IVT mRNA-encoded designer nucleases. This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA vaccines still suffer from decreased efficacy due to poor RNA stability in solution and in vivo and to limited expression of the payload mRNA; these are all pivotal issues that need to be carefully optimized for preclinical and clinical applications3–6.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN) (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The basic structure of mRNA, same as eukaryotic mRNA, is made up of (i) protein encoding ORF, surrounded by (ii) 5′ and 3′ UTRs, and (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′poly(A) tail at the end sides (Verbeke et al. 2019; Schlake et al. 2012; Sahin et al. 2014) (Fig. 1).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
In the citing paper
“Since the 3′-OH group in proximity to m7G is methylated, thus the ARCA cap analog can only bind the 5′ end of mRNA in forward orientation, which is recognized by the eukaryotic translation initiation factor 4E (eIF4E) to initiate ribosome recruitment and translation.74,125”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [74]
In the citing paper
“The host immune system can easily recognize unmodified mRNA or by-products formed during IVT of engineered mRNA as exogenous molecules.74”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [74]
In the citing paper
“Tfh cells recognize antigens on the APC surface and help to activate B cells, which in turn produce high-affinity virus-neutralizing antibodies.6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [57]
In the citing paper
“Tfh cells further help activate CD8+ cytotoxic T cells that may specifically recognize and eliminate virus-infected cells (Figure 1).6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [57]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA is susceptible to degradation and, thus, formulation buffers should be free of any ribonuclease contaminations2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Many other lipid nanoparticle–mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders2,4,8,12–14 (Tables 1,2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Moreover, mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies2,4,8,12–14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Compared with regular mRNA, self-amplifying RNA (also termed replicon), which was originally derived from an alphavirus genome, has similar basic elements (5′ cap, 5′ and 3′ untranslated regions, 3′ poly(A) tail) and a long coding region.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“After delivery into the cytoplasm, self-amplifying RNA (positive-strand mRNA) functions as a translation template for the production of the RDRP.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The coding region contains the sequences for an RNA-dependent RNA polymerase (RDRP), a promoter and structural viral proteins (also known as subgenomic sequence).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Meanwhile, the promoter in the negative-strand RNA is recognized by the RDRP, leading to the transcription of capped subgenomic RNA that encodes structural viral proteins.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“This self-amplification process allows the mass production of virions from limited amounts of virus at infection.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Replacing the subgenomic sequence by a gene of interest enables high-level expression of desired proteins.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The initial replication leads to negative-strand RNA, which acts as template for the generation of the positive-strand viral genome.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The transient replication generates double-stranded RNA (dsRNA) and, thus, self-amplifying RNA tends to activate innate immune pathways.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Moreover, the positive-strand mRNA serves as a genomic template for RDRP-mediated replication.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“To achieve effective translation, mRNA requires five structural elements, including the 5′ cap, 3′ poly(A) tail, protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The sequences of these elements regulate translation initiation, translation termination and post-transcriptional modification of mRNA molecules2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Compared with protein drugs, mRNA can supplement both cytoplasmic and large transmembranic proteins.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Relative to plasmid DNA (pDNA), mRNA possesses temporary bioactivity and functions outside the nucleus, leading to a more controllable protein expression and avoiding the potential insertion of the genome.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Protein-encoding mRNA has emerged as an attractive new technology for gene delivery.1”
From Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening (2019) · cites this paper as [1]
In the citing paper
“Robust induction of an immune response by a cancer vaccine requires efficient expression of the vaccine antigen-encoding mRNA specifically in DCs to achieve a high density of epitope-loaded MHCs.1,42”
From Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Flagged first, then by citations
1 of the 256 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Prieels, J.-P. et al. Mastering industrialization of cell therapy products. BioProcess Int. 10, S12–S15 (2012).
Cited by
Sorted by citations
Items 901–1,000 of 1,005
Specific Treatment Exists for SARS-CoV-2 ARDS
Kanwar, B. A., Khattak, A., Lee, J., Balentine, J., Kast, R. E., Oh, S.-S., Sergi, C., & Lee, J. (2021) · Vaccines · doi:10.3390/vaccines9060635 · Cited by 28
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 32
Schmidt, C., Haefner, E. S., Gerbeth, J., Beißert, T., Şahin, U., Perković, M., & Schnierle, B. S. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.036 · Cited by 28
More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing
Jensen, N., Barry, A., & Kelly, A. H. (2022) · Economy and Society · doi:10.1080/03085147.2022.2087899 · Cited by 31
Elwakil, M. M. A., Suzuki, R., Khalifa, A. M., Elshami, R. M., Isono, T., Elewa, Y. H. A., Sato, Y., Nakamura, T., Satoh, T., & Harashima, H. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303795 · Cited by 30
The European Regulatory Environment of RNA-Based Vaccines
Hinz, T., Kallen, K., Britten, C. M., Flamion, B., Granzer, U., Hoos, A., Huber, C., Khleif, S. N., Kreiter, S., Rammensee, H., et al. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_13 · Cited by 30
Self-citationStaels, W., Verdonck, Y., Heremans, Y., Leuckx, G., Groef, S. D., Heirman, C., de Koning, E. J. P., Gysemans, C. A., Thielemans, K., Baeyens, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4646-7 · Cited by 28
Ziegenhals, T., Frieling, R., Wolf, P., Göbel, K., Koch, S., Lohmann, M., Baiersdörfer, M., Fesser, S., Şahin, U., & Kuhn, A. N. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1291045 · Cited by 29
mRNA Vaccine Nanoplatforms and Innate Immunity
Wei, L., Dong, C., Zhu, W., & Wang, B. (2024) · Viruses · doi:10.3390/v16010120 · Cited by 28
Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines
Yıldız, A., Răileanu, C., & Beißert, T. (2024) · Viruses · doi:10.3390/v16040503 · Cited by 27
Immunotherapy in mastitis: state of knowledge, research gaps and way forward
Saleem, A., Saleem, S., Omonijo, F. A., Ganai, N. A., Ibeagha-Awemu, E. M., & Ahmad, S. M. (2024) · Veterinary Quarterly · doi:10.1080/01652176.2024.2363626 · Cited by 29
Leonard, R. A., Burke, K. N., Spreng, R. L., Macintyre, A. N., Tam, Y. K., Alameh, M., Weissman, D., & Heaton, N. S. (2024) · Nature Communications · doi:10.1038/s41467-024-52940-z · Cited by 27
Poly(β-amino ester) polymer library with monomer variation for mRNA delivery
Kim, H. L., Saravanakumar, G., Lee, S., Jang, S., Kang, S., Park, M., Sobha, S., Park, S. Y., Kim, S.-M., Lee, J.-A., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122896 · Cited by 28
Advances in drug delivery systems based on liposome-composite hydrogel microspheres
Yang, S., Li, Y., Li, S., Zhang, J., Huang, J., Ren, J., & Wu, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01369k · Cited by 27
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30
The Yin and Yang of nucleic acid-based therapy in the brain
Gustincich, S., Zucchelli, S., & Mallamaci, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.11.001 · Cited by 27
Improving the Angiogenic Potential of EPCs via Engineering with Synthetic Modified mRNAs
Steinle, H., Golombek, S., Behring, A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.005 · Cited by 27
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 29
Hasanzadeh, A., Radmanesh, F., Hosseini, E. S., Hashemzadeh, I., Kiani, J., Nourizadeh, H., Naseri, M., Fatahi, Y., Chegini, F., Madjd, Z., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00309 · Cited by 28
Sato, Y. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00705 · Cited by 29
Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders
Lee, M., Lee, I., & Wang, K. (2022) · Biomedicines · doi:10.3390/biomedicines10010158 · Cited by 27
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 30
Ionizable drug delivery systems for efficient and selective gene therapy
Zhang, Y., Guo, R., Chen, Y., Li, T., Du, W.-Z., Xiang, R., Guan, J., Li, Y., Huang, Y., Yu, Z., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00445-z · Cited by 27
M 3 RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction
Singh, R. D., Hillestad, M. L., Livia, C., Li, M., Alekseev, A. E., Witt, T. A., Stalboerger, P. G., Yamada, S., Terzic, A., & Behfar, A. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0445 · Cited by 27
Raab, M., Kostova, I., Peña‐Llopis, S., Fietz, D., Kressin, M., Aberoumandi, S. M., Ullrich, E., Becker, S., Sanhaji, M., & Strebhardt, K. (2023) · 癌症：英文版 · doi:10.1002/cac2.12511 · Cited by 27
Cai, H., Pang, Y., Ren, Z., Fu, X., & Jia, L. (2024) · BMC Medicine · doi:10.1186/s12916-024-03359-2 · Cited by 26
Optimization of the 5ʹ untranslated region of mRNA vaccines
Ma, Q., Zhang, X., Yang, J., Li, H., Hao, Y., & Feng, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-70792-x · Cited by 30
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations
Omidi, Y., Pourseif, M. M., Ansari, R. A., & Barar, J. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2419815 · Cited by 29
Buffer Specificity of Ionizable Lipid Nanoparticle Transfection Efficiency and Bulk Phase Transition
Carucci, C., Philipp, J., Müller, J., Sudarsan, A., Kostyurina, E., Blanchet, C. E., Schwierz, N., Parsons, D. F., Salis, A., & Rädler, J. O. (2025) · ACS Nano · doi:10.1021/acsnano.4c14098 · Cited by 27
Self-splicing RNA circularization facilitated by intact group I and II introns
Shen, Y. H., Li, B., Dong, L., Tang, W., Ren, J., Chen, F., Zheng, W., Yu, Y. F., Gao, L., & Wei, W. (2025) · Nature Communications · doi:10.1038/s41467-025-62607-y · Cited by 29
Abraham, M.-K., Peter, K., Michel, T., Wendel, H. P., Krajewski, S., & Wang, X. (2017) · Nanotheranostics · doi:10.7150/ntno.19449 · Cited by 27
Role of Telomeres Shortening in Atherogenesis: An Overview
Yegorov, Y. E., Poznyak, A. V., Nikiforov, N. G., Starodubova, A. V., & Orekhov, A. N. (2021) · Cells · doi:10.3390/cells10020395 · Cited by 26
Wojcik, R., Baranowski, M. R., Markiewicz, Ł., Kubacka, D., Bednarczyk, M., Baran, N., Wojtczak, A., Sikorski, P. J., Zuberek, J., Kowalska, J., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111941 · Cited by 26
Chang, C.-C., Tsou, H., Chang, H.-H., Chan, L. Y., Zhuo, G., Maeda, T., & Lin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010565 · Cited by 27
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Sommerauer, C., & Kutter, C. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00232.2022 · Cited by 27
Bradley, C. C., Wang, C., Gordon, A. J. E., Wen, A. X., Luna, P. N., Cooke, M. B., Kohrn, B. F., Kennedy, S. R., Avadhanula, V., Piedra, P. A., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01655-4 · Cited by 29
mRNA vaccines take on immune tolerance
Wardell, C. M., & Levings, M. K. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00880-0 · Cited by 27
Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics
Jiao, X., He, X., Qin, S., Yin, X., Song, T., Duan, X., Shi, H., Jiang, S., Zhang, Y., & Song, X. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1992 · Cited by 28
Clinical advancements in mRNA vaccines against viral infections
Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 25
Folding of mRNA‐DNA Origami for Controlled Translation and Viral Vector Packaging
Seitz, I., Saarinen, S., Wierzchowiecka, J., Kumpula, E., Shen, B., Cornelissen, J. J. L. M., Linko, V., Huiskonen, J. T., & Kostiainen, M. A. (2025) · Advanced Materials · doi:10.1002/adma.202417642 · Cited by 29
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 31
Liu, Z., Wu, J., Wang, N., Lin, Y., Song, R., Zhang, M., & Li, B. (2025) · Nature Communications · doi:10.1038/s41467-025-59501-y · Cited by 25
Transient hepatic reconstitution of trophic factors enhances aged immunity
Friedrich, M., Pham, J., Tian, J., Chen, H., Huang, J., Kehl, N., Liu, S., Lash, B., Chen, F., Wang, X., et al. (2025) · Nature · doi:10.1038/s41586-025-09873-4 · Cited by 29
Cancer neuroscience: signaling pathways and new therapeutic strategies for cancer
Zhang, S., Yuan, L., Lin, P., Yang, G., Zhou, X., Jinfu, X., Wu, M., & Huang, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02364-y · Cited by 29
Simultaneous and stoichiometric purification of hundreds of oligonucleotides
Pinto, A., Chen, S. X., & Zhang, D. Y. (2018) · Nature Communications · doi:10.1038/s41467-018-04870-w · Cited by 27
Vizirianakis, I. S., Miliotou, Α. N., Mystridis, G. A., Andriotis, E. G., Andreadis, I. I., Papadopoulou, L. C., & Fatouros, D. G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1605828 · Cited by 25
Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials
Ingels, J., Cock, L. D., Mayer, R. L., Devreker, P., Weening, K., Heyns, K., Lootens, N., Smet, S. D., Brusseel, M., Munter, S. D., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.08.005 · Cited by 25
Salomon, N., Selmi, A., Grunwitz, C. R., Kong, A. H., Stanganello, E., Neumaier, J., Petschenka, J., Diken, M., Kreiter, S., Türeci, Ö., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03134-9 · Cited by 26
Self-citationHantavirus Induced Kidney Disease
Mir, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.795340 · Cited by 25
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 26
Walle, T., Bajaj, S., Kraske, J. A., Rösner, T., Cussigh, C. S., Kälber, K. A., Müller, L. J., Strobel, S. B., Burghaus, J., Kallenberger, S. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00398-7 · Cited by 24
Lü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 28
A Thermal and Enzymatic Dual‐Stimuli Responsive DNA‐Based Nanomachine for Controlled mRNA Delivery
Li, F., Sun, X., Yang, J., Ren, J., Huang, M., Wang, S., & Yang, D. (2022) · Advanced Science · doi:10.1002/advs.202204905 · Cited by 25
Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers
Wang, H., Liu, X., Ai, X., Remant-Bahadur, K. C., Dick, T. A., Yan, B., Lu, T., Zhou, X., Luo, R., Liu, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020410 · Cited by 25
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
Larsen, S. E., Baldwin, S. L., & Coler, R. N. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.035 · Cited by 25
RNA Therapeutics: A Healthcare Paradigm Shift
Niazi, S. K. (2023) · Biomedicines · doi:10.3390/biomedicines11051275 · Cited by 25
Shi, L. D., Yang, J., Nie, Y., Huang, Y., & Gu, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301261 · Cited by 25
Hou, Y., Lin, S., Xia, J., Zhang, Y., Yin, Y., Huang, M., Xu, Y., Yang, W. Y., & Zhu, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102067 · Cited by 25
Site-Specific Covalent Conjugation of Modified mRNA by tRNA Guanine Transglycosylase
Ehret, F., Zhou, C. Y., Alexander, S. C., Zhang, D., & Devaraj, N. K. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00356 · Cited by 24
Nucleic acid therapies for cystic fibrosis
Sasaki, S., & Guo, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0696 · Cited by 24
Grandi, D. D., Dayeh, D. M., Kaur, K., Chen, Y., Henderson, S., Moon, Y., Bhowmick, A., Ihnat, P. M., Fu, Y., Muthusamy, K., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115692 · Cited by 23
İmani, S., Tagit, O., & Pichon, C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00807-1 · Cited by 25
RetractedUnruh, T., Götz, K., Vogel, C. S., Fröhlich, E., Scheurer, A., Porcar, L., & Steiniger, F. (2024) · ACS Nano · doi:10.1021/acsnano.4c02610 · Cited by 25
Beyond simple tails: poly(A) tail-mediated RNA epigenetic regulation
Liu, J., & Lu, F. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.06.013 · Cited by 25
Monitoring mRNA vaccine antigen expression in vivo using PET/CT
Blizard, G. S., Dwivedi, G., Pan, Y., Hou, C., Etersque, J. M., Said, H., Chevrier, A., Lavertu, M., Ni, H., Davis, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57446-w · Cited by 25
Yong, H., Tian, Y., Li, Z., Wang, C., Zhou, D., Liu, J., Huang, X., & Li, J. (2025) · Advanced Materials · doi:10.1002/adma.202414991 · Cited by 25
Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 28
Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
Razavi, R., Kegel, M., Muscat-Rivera, J., Weissman, D., & Melamed, J. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101566 · Cited by 28
Loomis, K. H., Kirschman, J. L., Bhosle, S. M., Bellamkonda, R. V., & Santangelo, P. J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01753j · Cited by 24
Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA
Zhou, X., Hao, R., Chen, C., Su, Z., Zhao, L., Luo, Z., & Xie, W. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.008 · Cited by 22
Sathian, B., Asim, M., Banerjee, I., Roy, B., Pizarro, A. B., Mancha, M. A., van Teijlingen, E., Kord‐Varkaneh, H., Mekkodathil, A. A., Subramanya, S. H., et al. (2021) · Nepal Journal of Epidemiology · doi:10.3126/nje.v11i1.36163 · Cited by 23
Elwakil, M. M. A., Gao, T., Isono, T., Sato, Y., Elewa, Y. H. A., Satoh, T., & Harashima, H. (2021) · Materials Horizons · doi:10.1039/d1mh00185j · Cited by 24
Wu, H. M., Wei, T., Yu, B., Cheng, R., Huang, F., Lu, X., Yan, Y., Wang, X., Liu, C., & Zhu, B. (2021) · RNA Biology · doi:10.1080/15476286.2021.1954808 · Cited by 26
Insights into the Evolving Roles of Circular RNAs in Cancer
Harper, K. L., Mottram, T. J., & Whitehouse, A. (2021) · Cancers · doi:10.3390/cancers13164180 · Cited by 25
Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid
Li, L., Long, J., Sang, Y., Wang, X., Zhou, X., Pan, Y., Cao, Y., Huang, H., Yang, Z., Yang, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.023 · Cited by 24
Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development
Cheng, R., Xu, Z., Luo, M., Wang, P., Cao, H., Jin, X., Zhou, W., Xiao, L., & Jiang, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab553 · Cited by 25
Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]
Jawalagatti, V., Kirthika, P., & Lee, J. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884862 · Cited by 24
Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells
Holzinger, A., & Abken, H. (2022) · Pharmacology · doi:10.1159/000525052 · Cited by 24
Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery
Broudic, K., Amberg, A., Schaefer, M. K., Spirkl, H.-P., Bernard, M., & Désert, P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116143 · Cited by 25
Nonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 25
Golba, B., Soete, M., Zhong, Z., Sanders, N. N., Prez, F. D., Houck, H. A., & Geest, B. G. D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301102 · Cited by 25
Sun, H., Zhang, Y., Wang, J., Su, J., Zhou, D., Yu, X., Xu, Y., & Yang, W. (2023) · Theranostics · doi:10.7150/thno.86466 · Cited by 27
Nussbaum, J. C., Cao, X., Railkar, R. A., Sachs, J. R., Spellman, D. S., Luk, J. A. M., Shaw, C. A., Cejas, P. J., Citron, M. P., Al-Ibrahim, M. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.062 · Cited by 24
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Goyal, F., Chattopadhyay, A., Navik, U., Jain, A., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300255 · Cited by 25
Deciphering the Immunogenicity of Monkeypox Proteins for Designing the Potential mRNA Vaccine
Shah, M., Jaan, S., Shehroz, M., Sarfraz, A., Asad, K., Wara, T. U., Zaman, A., Ullah, R., Ali, E. A., Nishan, U., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c07866 · Cited by 24
Coronavirus Disease 2019 Vaccine Development: An Overview
Sumirtanurdin, R., & Barliana, M. I. (2020) · Viral Immunology · doi:10.1089/vim.2020.0119 · Cited by 26
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy
Huang, L., Huang, Z., Zhang, Y., Lin, C., Zhao, Z., Li, R., Saw, P. E., & Xu, X. (2024) · Theranostics · doi:10.7150/thno.93745 · Cited by 24
Polypept(o)ides – Origins, synthesis, applications and future directions
Bauer, T. A., Simić, L., Guyse, J. F. R. V., Duro‐Castaño, A., Nebot, V. J., & Barz, M. (2024) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2024.101889 · Cited by 26
Selective Reduction of Esters to Access Aldehydes Using Fiddler Crab-Type Boranes
Dudás, Á., Gyömöre, Á., Mészáros, B. B., Gondár, S., Adamik, R., Fegyverneki, D., Papp, D., Otte, K. B., Ayala, S., Daru, J., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14596 · Cited by 23
Hendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 24
Bispecific antibodies: Potential immunotherapies for HIV treatment
Fabozzi, G., Pegu, A., Koup, R. A., & Petrovas, C. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.010 · Cited by 23
Ledo, A. M., Senra, A., Rilo-Alvarez, H., Borrajo, E., Vidal, A., Alonso, M. J., & García-Fuentes, M. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120016 · Cited by 23
Miyazaki, T., Uchida, S., Hatano, H., Miyahara, Y., Matsumoto, A., & Cabral, H. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.110028 · Cited by 21
Gene therapy avenues and COVID-19 vaccines
Abed, O. S. A. (2021) · Genes and Immunity · doi:10.1038/s41435-021-00136-6 · Cited by 23
Demelenne, A., Servais, A., Crommen, J., & Fillet, M. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462283 · Cited by 25
Liu, Y., Wan, H.-H., Tian, D., Xu, X., Bi, C., Zhan, X.-Y., Huang, B., Xu, Y., & Yan, L. (2021) · Materials · doi:10.3390/ma14164674 · Cited by 23
CRISPR-derived genome editing therapies: Progress from bench to bedside
Rees, H. A., Minella, A. C., Burnett, C. A., Komor, A. C., & Gaudelli, N. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.027 · Cited by 25
Elkhalifa, D. H., Rayan, M., Negmeldin, A. T., Elhissi, A. M. A., & Khalil, A. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112385 · Cited by 24
Metadata
- Authors
- Sahin, U., Karikó, K., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Karikó, Katalin
- Türeci, Özlem
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-09-19
- Volume
- 13
- Issue
- 10
- Pages
- 759-780
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1963706689
- Cited by
- 2,474
- References
- 256
- Citations by year
- 2026: 296 · 2025: 348 · 2024: 341 · 2023: 312 · 2022: 339 · 2021: 289 · 2020: 143 · 2019: 115 · 2018: 98 · 2017: 81 · 2016: 77 · 2015: 32 · 2014: 2
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- in vitro transcribed mRNA, mRNA therapeutics, mRNA vaccines, cancer immunotherapy, protein replacement therapy, genome editing, designer nucleases, immunogenicity, biopharmaceutical development
- MeSH terms
- Animals, Humans, Immunotherapy, Proteins, RNA, Messenger, Drug Design, Drug Delivery Systems, Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
